GC Aesthetics® Announces Growth and Expansion in Brazil
GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing Women Healthcare Aesthetic and Reconstructive Solutions, has announced today, its growth and expansion plans for the Brazilian market, the second largest Breast Augmentation market in the world.
GC Aesthetics® has been executing an ambitious journey repositioning the brand and portfolio to offer a smart, unique, and clinically proven safe range of products to meet the needs of Brazilian women and surgeons.
The Brazilian growth strategy includes 2 main pillars. First, the commercialization of all GC Aesthetics® products and solutions designed to support the best outcome for women's breast enhancement journey, before, during and after surgery. This unique portfolio not only stands out in today’s industry but is aligned with the company leadership position and growing plans evolving from Breast Implant Manufacturers to Solution Providers.
The Brazilian revenue growth of GC Aesthetics® is also linked to the ANVISA certificate (Brazilian Health Regulatory Agency) just obtained for the re-introduction of The Round Collection™ Breast Implants. This unique microtextured surface breast implant has been the preferred option by surgeons in Brazil: 99% of surveyed Plastic Surgeons consider The Round Collection™ as the trustable product in terms of safety and performance.
“According to our most recent survey, long-term proven safety & the unique type of micro texture are the 2 top reasons Brazilian Plastic Surgeons prefer The Round Collection Implants against competitors. We are beyond excited to be back in Brazil with this product and offer Surgeons and Patients, a proven long-term, safe and reliable medical device. Pre-orders of this product have exceeded what we had planned, and we are looking forward to a very bright, leading future in Brazil and in the world” – said Carlos Reis Pinto, CEO of GC Aesthetics®
“At GCA®, we are dedicated to advancing the science of medical aesthetics and delivering exceptional clinical, operational and commercial performance to be the preferred partner of surgeons and physicians worldwide, we are excited for The Round Collection™ re-entry in Brazil and are excited of presenting our brand as ONE GCA” – mentioned Ron Cosmas, CCO of GCA®.
GC Aesthetics® will be presenting the re-introduction of this product at the Jornada Paulista de Cirurgia Plástica, held from June 15th to the 18th at the WTC São Paulo, Brazil. Engineered and designed for performance The Round Collection™ breast implants have an unparalled long-term safety profile. The Round Collection™ by GC Aesthetics® is part of the largest European long-term clinical study for breast implants with exceptional results at 10 years and recently had data published in a one-of-a-kind 17 year patient follow-up with remarkable patient satisfaction.
About GC Aesthetics
GC Aesthetics is a long-established global medical technology company that develops, manufactures and markets a comprehensive range of proprietary aesthetic products that empower patients to feel confident and secure in their personal life journey.
Throughout its 40-year history, GCA has been dedicated to advancing the science of medical aesthetics and delivering high-quality breast implants for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries, and our products are supported by published 10-year clinical data demonstrating compelling safety and clinical effectiveness.
The company’s vertically integrated strategy enables exceptional clinical, operational and commercial performance, which allows GCA to provide competitively differentiated products to surgeons and patients. Through a culture of continuous innovation and dedication to customer-responsiveness, GCA has established itself as a leading provider of medical aesthetics solutions and the partner-of-choice for patients seeking to improve their lives.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005653/en/
Contact information
Fara Naomi Macias, Chief Marketing Officer
faramacias@gcaesthetics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 16:00:00 EET | Press release
Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more flexible. The diversified fuel procurement reduces external exposures and provides predicta
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 08:00:00 EET | Press release
OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines
26 th UN Tourism General Assembly kicks off in Riyadh7.11.2025 23:13:00 EET | Press release
The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebrate five decades of international collaboration under the theme “AI-Powered Tourism: Redefining the Future.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107012471/en/ 26th UN Tourism General Assembly kicks off in Riyadh The Assembly is hosted by Saudi Arabia’s Ministry of Tourism, with extensive cooperation and planning alongside UN Tourism and a wide range of partners. This collaboration underscores the Kingdom’s dedication to advancing the industry and facilitating impactful dialogue on the global stage. For half a century, UN Tourism has advanced
Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program7.11.2025 20:11:00 EET | Press release
Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, is proud to announce its sponsorship of the Gaming Awards segment at the Deloitte Technology Fast 50 Türkiye 2025 Program, organized in collaboration with Lorien Accelerator. The event will take place on December 10, 2025, and will recognize Turkey’s top high-growth companies across various industries, with a special focus on the dynamic gaming sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107671030/en/ Graphic: Xsolla As the Gaming Awards category sponsor, Xsolla will receive significant brand exposure through prominent logo placements across all event materials, including digital platforms, official event signage, and other promotional materials. In addition to this visibility, Xsolla’s participation includes an exclusive opportunity to engage in a panel discussion focused on Turkey’s rapidly growi
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 18:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston. IgA nephropathy is a lifelong progressive autoimmune disease often diagnosed in young people aged 10-30 years old that causes irreversible damage to the kidney function.2 It has no cure, and despite available treatments, approximately one in five patients experience renal failure within 10 years of diagnosis.3 By depleting cells that produce an abnormal protein called Gd-IgA1 implicated in the pathogenesis, mezagitamab targets early steps in the process lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
